American Battery Technology Company Hosts DOE Leadership to Showcase Commercial Technologies Strengthening U.S. Critical Minerals Supply Chains

AMERICAN BATTERY TECHNOLOGY Co (ABAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 American Battery Technology Company Announces Highest Ever Gross Profit and Successful Appeal for Reinstatement of $57 Million US Department of Energy Grant in Fourth Quarter FY2026 Financial Results Increase in gross profit of 86% through continued scale-up and impl

The US administration, according to a President Trump roundtable reported by Energy Metal News, committed over $2 billion to domestic battery and critical-mineral projects. The largest item is a $1.4 billion Defense Department loan to Sila Nanotechnologies, plus $400 million to Sunrise Energy Metals, $150 million to Niron Magnetics, and an $85.5 million equity investment in Strategic Bauxite. The article also highlights related company updates including NOMAD Power Solutions (NMAD).

Apple plans to launch its first foldable iPhone, priced around $2,000, alongside the new iPhone 18 Pro range on September 9. The company aims to enter the foldable smartphone market, currently led by Samsung and Huawei, and test consumer willingness to pay premium prices. The launch could drive a new upgrade cycle and help Apple focus on higher-margin devices amid rising production costs. Apple is also expected to emphasize AI advancements in its new devices.

Gilead Sciences (GILD) received FDA approval for Bixlenvo, a once-daily HIV treatment for adults with suppressed infections. Combining bictegravir and lenacapavir, it aims to simplify regimens for about 5% of U.S. HIV patients. Clinical trials showed effectiveness, and Gilead plans a quick launch. The list price is $4,595 for a 30-day supply. However, the market is narrow, and competition exists with Merck's Idvynso.

Altimmune (ALT) reported Q2 results, highlighting progress in three liver disease trials. The company launched a global Phase 3 trial for MASH, reported positive Phase 2 data for alcohol use disorder, and completed enrollment for a Phase 2 trial in alcohol-associated liver disease. Altimmune has no approved products and reported a net loss of $22.8 million, with cash reserves of $519 million as of June 30.

NVIDIA's equity investments in AI companies totaled $99 billion, up from $7 billion a year ago. Key investments include OpenAI ($30B), Hugging Face ($12.9B), and Anthropic ($10B). The company's Q2 2027 revenue was $96.2B, up 106% YoY, with data center revenue at $89B, up 117%. NVIDIA is also involved in $500B in AI infrastructure financing. Investments aim to secure customers, create dependencies, and gain equity upside, but also expose NVIDIA to market risks and potential regulatory scrutiny.